Researchers track Web&s presence in physician learning

Share this article:
Researchers tracking how physicians consume medical education online are mostly of the same mind when it comes to the growing role of eCME.

Pri-Med's Physician Insights Study shows physicians earned 13% of their hours online this past year—a 63% increase since 2003. Primary care physicians and psychiatrists tend to do more education online than other physicians studied, said Anne Goodrich, Pri-Med director, physician insights. “These clinicians…see so many patients per week and are so limited from a time perspective that [the] added advantage of online CME is particularly attractive.”

The ACCME 2006 annual report shows 27% of physician CME was done online last year, a 65% rise over 2005, and Manhattan Research's Taking the Pulse study, which measures responses of 1,353 practicing US physicians, showed that 16% of CME is being conducted online.

To be sure, “Live CME continues to be the dominant channel, in terms of where the bulk of CME is earned,” Goodrich explained, adding that online is not increasing at the expense of live. “That's important, because as we move toward curriculum learning, which is about providing a series of learning across channels, the point is to provide multiple touch points around messages.”

Share this article:
You must be a registered member of MMM to post a comment.


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...